Bas Ebaid 2025 Joint Meeting of the COSA ASM and IPOS Congress

Abstracts this author is presenting:

• Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC). — Wednesday Poster Session